

Subject Index, 1984

Vol. 34, Nos. 1-6

A

- ACR Patterns of Care Study, 75-85, 303**
Status of radiation treatment in the US, 75-85, 303
Background and methods, 76-79, 303
Future surveys, 84
Outcome for certain sites, 80-84
Study criteria, 79-80

Actinomycin D, 4

- Adenomas, colorectal, 167-176**
Classification of, 167-175
Detection of, 159
And endocavitary irradiation, 336
Malignant potential, 167-175
Management of patients with, 167-175
Recurring and synchronous lesions, 168, 170-171, 174-175
Polypectomy, 167-175

Adrenal tumors

- A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis (classic), 93-106

Adriamycin (doxorubicin, hydroxydaunorubicin), 3-4, 274, 277, 296

Alcohol

- Abuse combined with cigarette smoking, increased cancer incidence, 123

Arteriography

- Use in locating pheochromocytomas, 90

Asbestos, 44-56

- Death rates of asbestos workers, 50-53

- Exposure and neoplasia (classic), 48-56
Gastrointestinal cancer in asbestos workers, 54-55
Historical perspective (classic), 44-47
Smoking habits of asbestos workers, 52-54

Atrial metastasis (case report), 40-43

B

Bladder cancer

- Death rates for, 13, 15
Incidence of, 14
Mortality rates for, 9
Sexual rehabilitation, 71-72
And urostomy appliance, 71
Survival rates for, 20-21, 23, 283-284, 287, 289, 291

Bleomycin, 3, 119

Bone cancer

- Death rates for, 15
Incidence of, 14, 22
Mortality rates for, 9
Survival rates for, 287

Brain and central nervous system cancer

- Death rates for, 15
Incidence of, 14, 21-22
Mortality rates for, 9
Survival rates for, 23, 287

Breast cancer, 345-351

- Death rates for, 7, 12, 15, 17, 19
Estrogen and, 215-216, 220, 222, 224-226
Incidence of, 7, 14, 16, 21, 64 (letter), 346
In obese people, 122

Subject Index, 1984

Vol. 34, Nos. 1-6

A

- ACR Patterns of Care Study, 75-85, 303**
Status of radiation treatment in the US, 75-85, 303
Background and methods, 76-79, 303
Future surveys, 84
Outcome for certain sites, 80-84
Study criteria, 79-80

Actinomycin D, 4

- Adenomas, colorectal, 167-176**
Classification of, 167-175
Detection of, 159
And endocavitary irradiation, 336
Malignant potential, 167-175
Management of patients with, 167-175
Recurring and synchronous lesions, 168, 170-171, 174-175
Polypectomy, 167-175

Adrenal tumors

- A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis (classic), 93-106

Adriamycin (doxorubicin, hydroxydaunorubicin), 3-4, 274, 277, 296

Alcohol

- Abuse combined with cigarette smoking, increased cancer incidence, 123

Arteriography

- Use in locating pheochromocytomas, 90

Asbestos, 44-56

- Death rates of asbestos workers, 50-53

- Exposure and neoplasia (classic), 48-56
Gastrointestinal cancer in asbestos workers, 54-55
Historical perspective (classic), 44-47
Smoking habits of asbestos workers, 52-54

Atrial metastasis (case report), 40-43

B

Bladder cancer

- Death rates for, 13, 15
Incidence of, 14
Mortality rates for, 9
Sexual rehabilitation, 71-72
And urostomy appliance, 71
Survival rates for, 20-21, 23, 283-284, 287, 289, 291

Bleomycin, 3, 119

Bone cancer

- Death rates for, 15
Incidence of, 14, 22
Mortality rates for, 9
Survival rates for, 287

Brain and central nervous system cancer

- Death rates for, 15
Incidence of, 14, 21-22
Mortality rates for, 9
Survival rates for, 23, 287

Breast cancer, 345-351

- Death rates for, 7, 12, 15, 17, 19
Estrogen and, 215-216, 220, 222, 224-226
Incidence of, 7, 14, 16, 21, 64 (letter), 346
In obese people, 122

In people with diets high in fat, 122
 Mammography, 57-59, 64 (letter)
 Breast Cancer Detection
 Demonstration Projects, 57-58
 Mastectomy (Halsted radical), 346
 Mortality rates for, 9
 Screening for, 344
 Survival rates for, 20, 23, 283-284,
 287-289, 291

Butyrophonones, 5

C

Cancer, classification and staging of
 Request for suggestions on a unified
 system for, 304

Cancer, nutrition and, 121-126

Cancer control, 328-332, 340-344
 Definition of, 329, 340
 Interrelationship in the community of
 clinical research and, 340-344
 Clinical Oncology Program (COP),
 343
 Community Clinical Oncology
 Program (CCOP), 340, 343, 346-
 347
 Community Hospital Oncology
 Program (CHOP), 343
 Existing model of, 340-341
 Goal of, 340
 New model of, 340, 342
 Scientific approach to, 328-332
 Concept development and
 implementation, 328-329
 Phases of research process, 329-
 331

Cancer mortality among Mormons, 128
 Notice to readers, 128

**Cancer patients' attitudes toward
 hospice, 191-201**

Cancer prevention, 121-126
 ACS nutritional recommendations,
 121-126

**Cannabinoids, 5, but see correction for
 nabilone dosage, page 147**

**Case reports, 40-43, 110-117, 295-
 298**

Neurofibrosarcoma and the sign of
 Leser-Trélat, 295-298
 Primary cardiac osteosarcoma:
 multidisciplinary aspects applicable
 to extraskeletal osteosarcoma
 generally, 110-117

Secondary carcinoma involving the left
 atrium, 40-43

Cervical cancer, 306-327
 Age distribution by stage, 292
 Death rates for, 15
 And DES, 226
 Detection, epidemiology, diagnosis, and
 treatment of early lesions, 306-327
 Colposcopy and biopsy techniques,
 308-309, 312
 Condylomas, 307, 314, 316
 Epidemiology, 312-313
 Herpes virus, 313-314
 Papanicolaou smear, 307-308
 Papilloma virus, 314-316
 In pregnancy, 313
 Pretreatment evaluation, 316-318
 Screening techniques, 306-308
 Staging of lesions, 316-318
 Treatment of, 318-325
 Types of lesions, 306-325
 And estrogen, 226
 Incidence of, 14
 And smoking (letter), 302-303
 Survival rates for, 20, 23, 283-284,
 287-289, 291-293
 Treatment of, 80-81

Chemotherapy, 2-6, 345-351
 (See also, specific agents)
 Is aggressive adjuvant chemotherapy
 the Halsted radical of the '80s?,
 345-351
 Cytotoxic vs endocrine therapy
 debate, 346
 Nursing role in, 345
 Quality vs quantity of life, 345
 Risk of developing nonlymphocytic
 leukemia, 349
 Side effects of treatment, 345-351
 Duration of therapy, 3
 Inappropriate medical strategies, 3
 Long-term vs short-term effects of, 2
 In lung cancer, 273-278
 Multiple-agent approaches for
 alleviation of nausea and vomiting
 in, 5
 And ethics of patient requests in
 experimental medicine, 118-120
 Nausea and vomiting in, 2-6, 345
 Mechanisms of, 4
 Prevention of, 4-5
 Need for research in, 3-5
 In neurofibrosarcoma (case report),
 295-297
 In osteosarcoma, 116
 Sites of action, 4
 As symptomatic treatment, 188

Churg, Jacob, 45-46
 Historical perspective of asbestos
 (classic), 45-47

Cigarette smoking

- And alcohol abuse, increased cancer incidence, 123
- Cancer death rates due to, 125
- And cervical cancer (letter), 302-303
- Decline in (letter), 128
- In the genesis of small cell carcinoma, 269-270
- Smoking habits of asbestos workers, 52-54

Circumcision

- And penile cancer, correction (letter), 238

Cisplatin, 3-5, 119, 277-278, 296**Classics in oncology**, 44-56, 93-106, 282-294

- Asbestos exposure and neoplasia, 48-56
- Asbestos: historical perspective, 44-47
- A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis, 93-106
- Survival in untreated and treated cancer, 282-294

Clinical research, 340-344

- Interrelationship in the community of cancer control and, 340-344

CMF, 346**Colonoscopy**

- For colorectal cancer detection, 151-155, 160, 167
- In endocavitary irradiation for adenocarcinoma of the rectum, 333-339
- As follow-up in patients with colorectal adenomas, 170-175

Colorectal cancer, 130-176, 333-339

- Death rates for, 7, 12-13, 15, 17-18, 48, 52
- Endocavitary irradiation for adenocarcinoma of the rectum, 333-339
- Advantages of, 339
- As an alternative to surgery, 333-339
- Detection methods, 333
- Method of treatment, 334-335
- As palliation, 335-336
- Precautions, 336-339
- Selecting suitable patients for, 333-334
- Incidence of, 7, 14, 16, 21, 122, 131-

132, 149, 158

Mortality rates for, 9

Survival rates for, 20, 23, 158-159, 162, 283-284, 287-289, 291, 293

Third International Symposium on, 130-176

Colonoscopy, 151-155, 160

Endoscopy, 151-155

Fecal occult blood test, 131-132, 134-157

Management of patients with colorectal adenomas, 167-176

Proctosigmoidoscopy, 132, 151, 153-155, 158-166

Screening for, 132-134, 158-160

Colposcopy

For cervical cancer detection, 308-312

Computed tomography

- In esophageal cancer (letter), 127
- In locating pheochromocytomas, 90-91
- In osteosarcoma, 116

Condylomas

In cervical cancer, 307, 314, 316

Connective tissue cancer

- Death rates for, 15
- Incidence of, 9, 14, 22
- Mortality rates for, 9

Corrections, 147, 201, 238, 303

- Author's correction (letter), 303
- Dosage for nabilone, 147, 201
- Penile cancer and circumcision (letter), 238

Corticosteroids, 5**Cyclophosphamide**, 3, 274, 277, 296**Cystectomy**, 71-72

Sexual rehabilitation and, 71-72

Cytotoxic agents, 345-351

D**Dimethyl triazeno imidazole carboxamide (DTIC)**, 4**Disseminated cancer**, 356-357 (letter)**Doxorubicin** (See Adriamycin)

E**Endometrial cancer**, 210-231

Estrogen and, 210-231

Endoscopy

- In colorectal adenomas, 168-170, 172-173
- For colorectal cancer detection, 151-155
- In esophageal cancer (letter), 127
- As follow-up in patients with colorectal cancer, 170-175

Esophageal cancer

- Computed tomography in (letter), 127-128
- Death rates for, 13, 15
- Endoscopy in (letter), 127
- Incidence of, 14, 21
 - In alcohol abusers who smoke cigarettes, 123
 - In people with diets high in nitrate and nitrite, 123
 - In people with diets high in vitamins A and C, 123
- Roentgenography in (letter), 127
- Survival rates for, 23, 283, 287, 291

Esthesioneuroblastoma, 356 (letter)

Estrogen, 210-231

- Administration to menopausal women (opinions), 210-231
- Benefits, 210-211
- Risks, 211-216, 220-229
- Endometrial cancer and, 211-215, 220-229
- Other types of tumors, 226-228
- Recommendations for, 216

Ethics

- Patient requests in experimental medicine, 118-120

Etoposide, 274, 278

Experimental medicine

- Ethics of patient requests in (opinion), 118-120
- National Commission for the Protection of Human Subjects, 118

Eye cancer

- Death rates for, 15
- Incidence of, 14, 22

F

Fecal occult blood test, 134-157

- For colorectal cancer detection, 131, 132, 134-157, 172-174
- Diagnostic evaluation of positive test, 148-157

Guidelines, 154-155

Results of clinical trials, 154

Diet (letter), 352-353

- Factors that affect the test, 135-139
- Guidelines for administration of, 134-147
- Improving test performance, 139-142
- Screening results, 142-145

Feedback, 64, 127-128, 238-240, 299-303, 352-357

- Author's correction, 303
- Cancer and pregnancy, 238-240
- Decline in smoking, 128
- Esophageal cancer, 127-128
- Esthesioneuroblastoma, 356
- Fecal occult blood test, 352-353
- Growth of disseminated cancer, 356-357
- Immuno-augmentative therapy, 356
- Malignant melanoma, 353-354
- Mammography, 64
- Penile cancer and circumcision, correction, 238
- Sexual rehabilitation, 354-355
- Smoking and cervical cancer, 302-303
- Thyroid cancer, 299-302

5-Fluorouracil, 119

Floxuridine, 3-4

G

Gallbladder cancer

- Incidence of, 122
- In obese people, 122

Gastrointestinal cancer

- Incidence of, 54-55, 123
- In asbestos workers, 54-55
- In people with diets high in cruciferous vegetables, 123

H

Hammond, E. Cuyler, 45-46

- Historical perspective of asbestos (classic), 45-47

Herpes virus

- Transmissible agent of cervical cancer, 313-314

Hodgkin's disease

- Chemotherapy for, 3
- Death rates for, 15
- Incidence of, 14
- Mortality rates for, 9
- Survival rates for, 20, 23

Treatment of, 80-81
Tribute to Henry S. Kaplan, 206-209

Hospice, 178-205

Cancer patients' attitudes toward, 191-201
According to gender, 195-197, 199
Likelihood of using various programs, 193, 197
Professional vs patient priorities, 195, 198
Concept of, 202-203
Incidence of in US, 191
Nursing role in, 204-205
An oncologist's viewpoint on, 178-182
Problems of, 180-181
Research on psychosocial aspects and control of symptoms, 181-182
Special program features, 178-180
Problems of, 183-190
Appropriate care, 184-185
Case studies, 185-188
Chemotherapy as symptomatic treatment, 188
Cost effectiveness, 189
Identification of the dying process, 188-189

Hydroxydaunorubicin (See Adriamycin)

Hysterectomy

As preventive treatment in early cervical cancer, 319-320

I

¹³¹I-Metaiodobenzylguanidine, 86-92
In locating pheochromocytomas with scintigraphy, 86-92

Immuno-augmentative therapy
(unproven methods), 232-237, 356

Insurability and level I (in situ) melanoma, 107-109, 353-354

K

Kaplan, Henry Seymour, 206-209
Contributions to radiology, 207-209
Medical linear accelerator, 209
Reflections on his life, 209
Tributes to, 206-209
Work on lymphomas and Hodgkin's disease, 207-209

Kidney cancer

Death rates for, 15
Incidence of, 14, 21-22

In obese people, 122
Mortality rates for, 9
Survival rates for, 20, 23, 289

L

Laryngeal cancer

Death rates for, 15
Incidence of, 14
In alcohol abusers who smoke cigarettes, 123
In people with diets high in vitamin A, 123
Survival rates for, 23, 35, 283, 287-289, 291
Treatment of, 81-83

Leser-Trélat, sign of

And neurofibrosarcoma (case report), 295-298

Leukemia

Death rates for, 7, 12-13, 15, 17, 19
Incidence of, 7, 14, 16, 22
Mortality rates for, 9
Resulting from cytotoxic chemotherapy, 349
Survival rates for, 20, 23

Liver cancer

Death rates for, 12-13, 15
Incidence of, 14, 21-22
In alcohol abusers, 123
Survival rates for, 283

Lomustine, 274, 277

Lung cancer

Asbestos-exposure related, 44-45, 48-55
And smoking habits, 52
Death rates for, 7, 12-13, 15, 17, 19, 51-52
Incidence of, 7, 14, 16, 21, 149
In people with diets high in vitamin A, 123
Metastasizing to the left atrium (case report), 40-43
Mortality rates for, 9
Rate of detection during screening for oral cancer, 266-267
Small cell carcinoma of the lung, 269-281
Biology and pathology of, 269-271
Clinical features of, 272-273
Cushing's syndrome, 272
Epidemiology of, 269
Treatment of, 273-278
Survival rates for, 20, 23, 273-277, 283, 287, 291

Lymphomas

- Death rates for, 7, 15
- Incidence of, 7, 14, 22
- Mortality rates for, 9
- Survival rates for, 23
- Tribute to Henry S. Kaplan, 206-209

M

Macrobiotic diets (unproven methods), 60-63

Malignant melanoma, 107-109

- Diagnosing level I (in situ), 107-109, 353-354 (letter)
- Incidence of, 107
- Insurability and level I (in situ) melanoma, 107-109, 353-354 (letter)
- And pregnancy (letter), 238-240
- Melanocytic dysplasia (letter), 353-354
- New Mexico Skin Cancer Project Survey, 107-109

Mammography

- The continuing challenge of (opinion), 57-59
- ACR guidelines, 59
- Breast Cancer Detection Demonstration Projects (BCDDPs), 57-58
- Costs of, 58
- Warren, Stafford, 57
- Statistics (letter), 64

Medical linear accelerator, 209

Mesothelioma

- Asbestos-related, 45, 48, 51, 53-55

Methotrexate, 274, 277

- And leucovorin rescue, 119

Metochlorpropamide, 5

Mitomycin C, 296

Mormons

- Cancer mortality among, 128
- Cervical cancer in (letter), 302

Multiple myeloma

- Death rates for, 15
- Incidence of, 14
- Survival rates for, 20

Myocardial infarction

- And estrogen, 216

N

Nabilone

- Dosage for (correction), 147, 201
- To prevent nausea and vomiting from chemotherapy, 2-6, 147, 201

Neurofibrosarcoma (case report), 295-298

- And the sign of Leser-Trélat (case report), 295-298
- Chemotherapy for, 296
- Radiation therapy for, 295

Nitrogen mustard, 4

Nolvadex, 346, 348

Nursing

- Role in dealing with side effects of chemotherapy, 345
- Role in hospice, 204-205

Nutrition and cancer, 121-126

- ACS recommendations, cause and prevention, 121-123
- ACS research, 126
- Cancer Prevention Studies I and II, 126
- Background, 124-125
- Dietary practice review, 123-124
- Artificial sweeteners, 124
- Cholesterol, 124
- Coffee, 124
- Cooking at high temperatures, 124
- Food additives, 124
- Selenium, 124
- Vitamin E, 124
- Migrating populations study, 125-126

O

Opinions, 57-59, 118-120, 210-231, 345-351

- Benefits of estrogen to the menopausal woman outweigh the risks of developing endometrial cancer, 210-231
- Con, 220-231
- Pro, 210-219
- The continuing challenge of mammography, 57-59
- The ethics of patient requests in experimental medicine, 118-120
- Is aggressive adjuvant chemotherapy the Halsted radical of the '80s?, 345-351

- Oral cancer**, 24-39, 262-268
AJC staging of, 26-27
Causes of, 24, 27
Death rates for, 7, 15, 17-18
Diagnosis of, 26
Incidence of, 7, 14, 16, 21, 24-25
 In alcohol abusers who smoke cigarettes, 123
Metastases in, 29
Pathology of, 29, 33-34
Radiation therapy for, 29
Screening for, 262-268
And smokeless tobacco, 242-261
Of the salivary glands, 24-39
 Benign tumors, 29-38
 Malignant tumors, 30-38
 Radiation therapy for, 29
 Surgery for, 27-29, 37-38
 Treatment of, 27, 37-38, 81-82
 Tumor classification, 26-27
 Warthin's tumor, 24, 30-34
 Survival rates for, 35-37, 262, 283-284, 291
- Osteosarcoma** (case report), 110-117
Diagnosis of, 110-117
- Ovarian cancer**
Death rates for, 7, 12, 15
And estrogen, 226-227
Incidence of, 7, 14, 21
Mortality rates for, 9
Survival rates for, 20, 23, 283, 287, 291

P

- Pancreatic cancer**
Death rates for, 7, 12-13, 15, 17
Incidence of, 7, 14, 16, 21
Mortality rates for, 9
Survival rates for, 283, 291
- Papanicolaou smear**, 307-308
- Papilloma virus**
Transmissible agent of cervical cancer, 314-316
- Penile cancer**
Correction (letter), 238
Sexual rehabilitation in, 73
- Phenothiazines**, 5

- Pheochromocytomas**, 86-92
A case of bilateral, completely latent, adrenal tumor and concurrent nephritis with changes in the circulatory system and retinitis (classic), 93-106
And hypertension, 86, 89
Use of arteriography to locate, 90
Use of computed tomography to locate, 90
Use of scintigraphy to locate, 86-91
Use of ultrasonography to locate, 90

Prednisone, 346

- Pregnancy**
And cancer (letter), 238-240
And cervical cancer, 313

Procarbazine, 277

- Proctosigmoidoscopy**
Benefits vs risks, 158-160
For colorectal cancer detection, 132, 151, 153-155, 158-166, 333
Examiners, knowledge and proficiency of, 161-163
As follow-up for colorectal adenomas, 170-175
Recommendations, 164
Types of, 160

- Prostate cancer**
Age distribution by stage, 293
Death rates for, 7, 13, 15, 17, 19
Incidence of, 7, 14, 16, 21
Mortality rates for, 9
Sexual rehabilitation in, 69-70
Survival rates for, 20, 23, 283-284, 287, 289, 291-293
Treatment of, 82-84

R

- Radiation therapy**, 75-85
ACR Patterns of Care Study, 75-85
Author's correction (letter), 303
In cervical cancer, 80
In colorectal cancer, 151, 154, 333-339
In lung cancer, 275-277
In neurofibrosarcoma (case report), 295
Tribute to Henry S. Kaplan, 206-209
- Rectal cancer**
(See colorectal cancer)

S

Salivary gland tumors, 24-39

- AJC staging of, 26-27
- Causes of, 24, 27
- Radiation therapy for, 29
- Surgery for, 28-29, 37-38
- Survival rates for, 35-38
- Treatment of, 27-28, 37-38
- Types of, 29-38
 - Benign, 29-38
 - Malignant, 30-38

Scintigraphy

- Detection of osteosarcoma with, 110-117
- Use in locating pheochromocytomas, 86-92

Screening

- For breast cancer, 57, 59, 344
- Cancer Prevention Studies I and II, 126
- For cervical cancer, 306-308
- For colorectal cancer, 130-133, 134-147, 166, 333
- With the fecal occult blood test, 142-145
- Interrelationship of cancer control and clinical research in the community, 340-344
- For oral and oropharyngeal squamous carcinomas, 262-268

Secondary tumors

- Left atrial (case report), 40-43

Selikoff, Irving, 45-47

- Historical perspective of asbestos-related disease (classic), 45-47

Sexual rehabilitation, 66-74

- Discussing the problem, 66-69
- In urologic cancer patients, 66-74, 354-355 (letter)

Skin cancer

- Death rates for, 7, 14
- Incidence of, 7, 14, 21, 75
- Mortality rates for, 9
- New Mexico Skin Cancer Project Survey, 107-109
- And malignant melanoma, 107-109
- Survival rates for, 23, 287

Small cell carcinoma, lung, 269-281

Squamous cell cancer, 118-120

- Chemotherapy in, 118-120

Statistics, cancer, 7-23

- (See also, specific sites)

ACS estimates of incidence and death, 7-23, 75

Death rates, 8, 22, 125

- By geographic location, 17-19
- By leading causes among children, 22

By site and sex, 7, 12-13, 15

Incidence

- By geographic location, 16
- By site and sex, 7, 14
- By site for children, 22
- By stage at diagnosis, 21

Mortality rates

- By leading cancer sites, 9
- By leading causes, 8
- Leading causes by age and sex, 10-11

Survival rates

- By site and race, 20
- Trends, by site and race, 23

Stomach cancer

- Death rates for, 12-13, 15, 17, 19, 48, 52, 54
- Incidence of, 14, 16, 21, 54-55
- In obese people, 122
- In people with diets high in nitrate and nitrite, 123
- In people with diets high in vitamin C, 123
- Mortality rates for, 9
- Survival rates for, 20, 23, 283-284, 287, 291

Streptozotocin, 4

Surgery

- In colorectal cancer, 168-170
- In lung cancer, 273-276
- In malignant melanoma (letter), 238-240
- In primary cardiac osteosarcoma, 112, 116
- In salivary gland tumors, 28-29, 37-38

Survival in untreated and treated

- cancer (classic), 282-294**
- Connecticut cancer register, 284-293
- Survival rates by site, 287-289, 291-293

Sympathetic nervous system cancer

- Incidence of, 22

T

Tamoxifen, 346, 348

Teniposide, 278

Testicular cancer

- Chemotherapy in, 3
- Death rates for, 15
- Incidence of, 14
- Mortality rates for, 9
- Sexual rehabilitation and, 72-73
- Survival rates for, 23
- Treatment of, 80-82

Thyroid cancer

- Death rates for, 15
- Incidence of, 14, 21
- Iodine-131 and thyroid suppression as treatment for (letter), 299-302
- Survival rates for, 23, 284, 287-289

TNM cancer classification and staging system, 304

- Request for suggestions on a unified system, 304

Tobacco, smokeless, 242-261

- A comparison of use in rural and urban teenagers, 248-261
- Age, sex, and clinical appearance, 249-251
- Anatomic location of lesions, 249-250, 252-255
- Classification of lesions, 251, 254
- Future research, 259-260
- Habituating effects of, 260-261
- Length of exposure, 250, 254, 258-260
- Level of dental care in study subjects, 257
- Symptomatology, race, and social habits, 250, 256
- Epidemiologic data from India, 243-244
- Increased promotion and use of, 242-243, 247-248
- Malignant transformation of leukoplakia, 245
- And oral cancer, 242-247

U

Ultrasonography

- Use in locating pheochromocytomas, 90

Unproven methods of cancer management, 60-63, 232-237

- Immuno-augmentative therapy, 232-237, 356 (letter)
- Macrobiotic diets, 60-63

Untreated cancer, survival in, 282-294

Urinary cancer

- Death rates for, 7, 13, 15
- Incidence of, 7, 14, 21
- Mortality rates for, 9
- Survival rates for, 20, 23

Urologic cancer, 66-74

- Sexual rehabilitation of patients with, 66-74, 354-355 (letter)
- Bladder cancer, 71-72
- Discussing the problem, 66-69
- Penile cancer, 73
- Prostate cancer, 69-70
- Testicular cancer, 72-73

Urostomy appliance

- Sexual rehabilitation and, 71

Uterine cancer

- Death rates for, 7, 12, 15, 17, 19
- Incidence of, 7, 14, 16, 21
- In obese people, 122
- Mortality rates for, 9
- Survival rates for, 20, 23, 287, 289, 293

V

Vinblastine, 3

Vincristine, 274, 277, 296, 346

Vindesine, 278

Viral agents

- As causes of cervical cancer, 313-316

W

Warren, Stafford

- Mammography, 57

Author Index, 1984

Vol. 34, Nos. 1-6

A

Adams AB, 183-190
Albain KS, 269-281
Averette HE, 306-327

B

Bachman LH, 238
Bagshaw MA, 208-209
Baker HW, 304
Barnes CA, 353
Barsa P, 262-268
Beierwaltes WH, 86-92
Bitran JD, 269-281
Braunstein GD, 210-219
Breslow DM, 191-201

C

Caldronery RD, 40-43
Churg J, 48-56
Copp JE, 86-92
Crane LA, 191-201
Crespi M, 158-166
Crowley LV, 356-357
Cullen JW, 328-332
Cutler SJ, 282-294

D

DeCosse JJ, 357
Diamond JJ, 75-85
Dodd GD, 57-59
Donegan WL, 240
Durant JR, 2-6

E

Elliott EC, 40-43
Ellis FH, Jr., 127-128
Enck RE, 340-344
von Eschenbach AC, 66-74

F

Fleisher M, 134-147, 352-353
Fordham EW, 110-117
Fränkel F, 93-106

G

Ganz PA, 191-201
Garfinkel L, 44-47, 64
Gilbert I, 354-355
Gilbertsen VA, 158-166
Gnauck R, 134-147
Golomb HM, 269-281
Gonzalez J, 66-74
Goren CC, 110-117
Goulston K, 148-157
Graney MJ, 333-339
Gregor DH, 352
Greene PE, 204-205
Greenwald P, 328-332
Greer RO, Jr., 248-261
Griswold MH, 282-294

H

Hammond EC, 48-56
Hanks GE, 75-85
Hawk JC, Jr., 238-239
Henderson BE, 356
Henkin RE, 300-301
Hinson EJ, 333-339
Hoffman PC, 269-281
Holleb AI, 206-207
Hunt RH, 148-157

J

Jacobsen GA, 202-203

K

Kern S, 302

Kopecky K, 299-300
Kramer S, 75-85, 303
Kushner R, 345-351

L

Lambert R, 167-176
Leiferman KM, 295-298
Levene A, 239
Lindenmuth JE, 248-261
Luebke DC, 353
Lyon JL, 302-303

M

MacDonald N, 178-182
MacLean CJ, 75-85
Macrae FA, 134-147
Mashberg A, 262-268
McCall AR, 110-117
McKenna RJ, 24-39
Meyers JA, 64
Micetich KC, 118-120
Morrow CP, 220-231

N

Nankin HR, 299
Nelson JH, Jr., 306-327

P

Park H-M, 299-300
Poulson TC, 248-261
Preston-Martin S, 356

R

Rainey LC, 191-201
Redman JC, 107-109, 353-354

Reinig JW, 127
Richart RM, 306-327
Rosenberg MS, 110-117
Rozek S, 110-117
Rubin J, 295-298

S

Schneiderman H, 110-117
Schover LR, 66-74, 355
Selikoff IJ, 48-56
Shapiro B, 86-92
Sherlock P, 158-166
Shimkin MB, 282-294
Silverberg E, 7-23
Sischy B, 333-339
Sisson JC, 86-92
Smalley SR, 295-298
Smith DB, 66-74
Sobin LH, 167-176, 304
Squier CA, 242-247
Stalder GA, 167-176
Strohlein JR, 148-157

T

Thomasma DC, 118-120

W

Wanebo HJ, 301-302
Waye JD, 167-176
Weisburger JH, 128
Weissman GS, 158-166
Winawer SJ, 130-133, 158-166

Z

Zavertnik JJ, 356

